1. Home
  2. LQDA vs HDL Comparison

LQDA vs HDL Comparison

Compare LQDA & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • HDL
  • Stock Information
  • Founded
  • LQDA 2004
  • HDL 2016
  • Country
  • LQDA United States
  • HDL Singapore
  • Employees
  • LQDA N/A
  • HDL N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • HDL Restaurants
  • Sector
  • LQDA Health Care
  • HDL Consumer Discretionary
  • Exchange
  • LQDA Nasdaq
  • HDL Nasdaq
  • Market Cap
  • LQDA 1.4B
  • HDL 1.6B
  • IPO Year
  • LQDA 2018
  • HDL 2024
  • Fundamental
  • Price
  • LQDA $14.92
  • HDL $20.44
  • Analyst Decision
  • LQDA Strong Buy
  • HDL
  • Analyst Count
  • LQDA 8
  • HDL 0
  • Target Price
  • LQDA $27.13
  • HDL N/A
  • AVG Volume (30 Days)
  • LQDA 2.1M
  • HDL 1.4K
  • Earning Date
  • LQDA 05-08-2025
  • HDL 05-21-2025
  • Dividend Yield
  • LQDA N/A
  • HDL N/A
  • EPS Growth
  • LQDA N/A
  • HDL 110.82
  • EPS
  • LQDA N/A
  • HDL 0.06
  • Revenue
  • LQDA $14,144,000.00
  • HDL $789,766,000.00
  • Revenue This Year
  • LQDA $224.65
  • HDL $17.95
  • Revenue Next Year
  • LQDA $250.54
  • HDL $13.32
  • P/E Ratio
  • LQDA N/A
  • HDL $34.83
  • Revenue Growth
  • LQDA N/A
  • HDL 10.91
  • 52 Week Low
  • LQDA $8.26
  • HDL $13.94
  • 52 Week High
  • LQDA $19.41
  • HDL $30.00
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.94
  • HDL N/A
  • Support Level
  • LQDA $13.94
  • HDL N/A
  • Resistance Level
  • LQDA $17.88
  • HDL N/A
  • Average True Range (ATR)
  • LQDA 1.40
  • HDL 0.00
  • MACD
  • LQDA -0.33
  • HDL 0.00
  • Stochastic Oscillator
  • LQDA 17.92
  • HDL 0.00

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.

Share on Social Networks: